medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2010, Number 05-06

<< Back Next >>

Medicina & Laboratorio 2010; 16 (05-06)

Paracoccidioidomicosis y artritis reumatoide. Una rara asociación

Cardona GMC, Martínez LCI, Ramírez BJD

Language: Spanish
References: 37
Page: 243-252
PDF size: 452.42 Kb.


ABSTRACT

Paracoccidioidomycosis is the most common deep mycosis in Latin America. It mainly affects adults and produces chronic lesions in skin, mucous membranes and lungs. The diagnosis is based on the demonstration of multiple budding yeast in clinical specimens and culture to demonstrate dimorphism. Reported cases have increased in part due to diseases such as AIDS and the advent of new immunosuppressive therapies. We report the clinical manifestations of a patient with rheumatoid arthritis at an advanced stage, who despite the lack of modulating therapy for his underlying disease, presents with acute/subacute paracoccidioidomycosis.


REFERENCES

  1. Restrepo A, Tobón A. Paracoccidioides Brasiliensis. In Mandell GL, Douglas RG, Bennett JE, eds. Principles and Practice of Infectious Diseases. 7th Edition. Philadelphia: Churchill Livingstone. 2009; 3357-3363.

  2. Londero A, Ramos C. Paracoccidioidomicosis: estudio clínico-5. micológico de 260 casos observados no interior do Estado do Rio Grande do Sul. J Pneumol 1990; 16: 129-132.

  3. Cadavid D, Restrepo A. Factors associated with Paracoccidiodes brasiliensis infection among permanent residents of three endemic areas in Colombia. Epidemiol Infect 1993; 111: 121-133.

  4. Tobón AM, Agudelo CA, Restrepo CA, et al. Adrenal function status in patients with paracoccidioidomycosis after prolonged post-therapy follow- up. Am J Trop Med Hyg 2010; 83: 111-114.

  5. Zaputovich F, Cardozo L, Di Martino B. Paracoccidioidomicosis en paciente HIV. Rev Esp Patol 2008; 41: 150-153.

  6. Theodoro RC, Bagagli E, Oliveira C. Phylogenetic analysis of PRP8 intein in Paracoccidioides brasiliensis species complex. Fungal Genet Biol 2008; 45: 1284-1291.

  7. Calle D, Rosero DS, Orozco LC, Camargo D, Castaneda E, Restrepo A. Paracoccidioidomycosis in Colombia: an ecological study. Epidemiol Infect 2001; 126: 309-315.

  8. Coutinho ZF, Silva D, Lazera M, et al. Paracoccidioidomycosis mortality in Brazil (1980-1995). Cad Saude Publica 2002; 18: 1441-1454.

  9. Restrepo A, McEwen JG, Castaneda E. The habitat of Paracoccidioides brasiliensis: how far from solving the riddle? Med Mycol 2001; 39: 233-241.

  10. Benard G, Kavakama J, Mendes-Giannini MJ, Kono A, Duarte AJ, Shikanai-Yasuda MA. Contribution to the natural history of paracoccidioidomycosis: identification of the primary pulmonary infection in the severe acute form of the disease--a case report. Clin Infect Dis 2005; 40: e1-e4.

  11. Restrepo A. Morphological aspects of Paracoccidioides brasiliensis in lymph nodes: implications for the prolonged latency of paracoccidioidomycosis? Med Mycol 2000; 38: 317-322.

  12. Travassos LR, Taborda CP, Colombo AL. Treatment options for paracoccidioidomycosis and new strategies investigated. Expert Rev Anti Infect Ther 2008; 6: 251-262.

  13. Pereira RM, Bucaretchi F, Barison Ede M, Hessel G, Tresoldi AT. Paracoccidioidomycosis in children: clinical presentation, follow-up and outcome. Rev Inst Med Trop Sao Paulo 2004; 46: 127-131.

  14. Restrepo A, Benard G, de Castro CC, Agudelo CA, Tobon AM. Pulmonary paracoccidioidomycosis. Semin Respir Crit Care Med 2008; 29: 182-197.

  15. Colombo AL, Faical S, Kater CE. Systematic evaluation of the adrenocortical function in patients with paracoccidioidomycosis. Mycopathologia 1994; 127: 89-93.

  16. Amstalden EM, Xavier R, Kattapuram SV, Bertolo MB, Swartz MN, Rosenberg AE. Paracoccidioidomycosis of bones and joints. A clinical, radiologic, and pathologic study of 9 cases. Medicine (Baltimore) 1996; 75: 213-225.

  17. Severo LC, Kauer CL, Oliveira F, Rigatti RA, Hartmann AA, Londero AT. Paracoccidioidomycosis of the male genital tract. Report of eleven cases and a review of Brazilian literature. Rev Inst Med Trop Sao Paulo 2000; 42: 38-40.

  18. Tobon AM, Agudelo CA, Osorio ML, et al. Residual pulmonary abnormalities in adult patients with chronic paracoccidioidomycosis: prolonged follow-up after itraconazole therapy. Clin Infect Dis 2003; 37: 898-904.

  19. Brummer E, Castaneda E, Restrepo A. Paracoccidioidomycosis: an update. Clin Microbiol Rev 1993; 6: 89-117.

  20. de Camargo ZP. Serology of paracoccidioidomycosis. Mycopathologia 2008; 165: 289-302.

  21. Marques da Silva SH, Queiroz-Telles F, Colombo AL, Blotta MH, Lopes JD, Pires De Camargo Z. Monitoring gp43 antigenemia in Paracoccidioidomycosis patients during therapy. J Clin Microbiol 2004; 42: 2419-2424.

  22. Gomes GM, Cisalpino PS, Taborda CP, de Camargo ZP. PCR for diagnosis of paracoccidioidomycosis. J Clin Microbiol 2000; 38: 3478-3480.

  23. Menezes V, Soares B, Fontes C. Drugs for treating paracoccidioidomycosis. Cochrane Database Syst Rev 2006; 19: CD004967.

  24. Jaruratanasirikul S, Kleepkaew A. Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. Eur J Clin Pharmacol 1997; 52: 235-237.

  25. Lange D, Pavao JH, Wu J, Klausner M. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J Clin Pharmacol 1997; 37:535-540.

  26. Chin TW, Loeb M, Fong IW. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. Antimicrob Agents Chemother 1995; 39: 1671-1675.

  27. Queiroz-Telles F, Goldani LZ, Schlamm HT, Goodrich JM, Espinel-Ingroff A, Shikanai- Yasuda MA. An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis. Clin Infect Dis 2007; 45: 1462-1469.

  28. Morejon KM, Machado AA, Martinez R. Paracoccidioidomycosis in patients infected with and not infected with human immunodeficiency virus: a case-control study. Am J Trop Med Hyg 2009; 80: 359-366.

  29. de Camargo ZP, de Franco MF. Current knowledge on pathogenesis and immunodiagnosis of paracoccidioidomycosis. Rev Iberoam Micol 2000; 17: 41-48.

  30. Gonzalez A, Sahaza JH, Ortiz BL, Restrepo A, Cano LE. Production of pro-inflammatory cytokines during the early stages of experimental Paracoccidioides brasiliensis infection. Med Mycol 2003; 41: 391-399.

  31. Mamoni RL, Nouer SA, Oliveira SJ, et al. Enhanced production of specific IgG4, IgE, IgA and TGF-beta in sera from patients with the juvenile form of paracoccidioidomycosis. Med Mycol 2002; 40: 153-159.

  32. Aguado MT, Lambris JD, Tsokos GC, et al. Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b. J Clin Invest 1985; 76: 1418-1426.

  33. Karhawi AS, Colombo AL, Salomao R. Production of IFN-gamma is impaired in patients with paracoccidioidomycosis during active disease and is restored after clinical remission. Med Mycol 2000; 38: 225-229.

  34. Sugar AM, Restrepo A, Stevens DA. Paracoccidioidomycosis in the immunosuppressed host: report of a case and review of the literature. Am Rev Respir Dis 1984; 129: 340-342.

  35. Kashino SS, Fazioli RA, Cafalli-Favati C, et al. Resistance to Paracoccidioides brasiliensis infection is linked to a preferential Th1 immune response, whereas susceptibility is associated with absence of IFN-gamma production. J Interferon Cytokine Res 2000; 20: 89-97.

  36. Smeenk R, Brinkman K, van den Brink H, et al. Antibodies to DNA in patients with systemic lupus erythematosus. Their role in the diagnosis, the follow-up and the pathogenesis of the disease. Clin Rheumatol 1990; 9: 100-110.

  37. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358: 903-911.




2020     |     www.medigraphic.com